biostudies-literatureUnknownLeonard LNCI NIH HHSMD Anderson Cancer Center<h4>Background</h4>In patients with hormone receptor-positive (HR⁺), HER2-negative breast cancer, there is a lack of data available to define optimal axillary management strategies after neoadjuvant endocrine therapy (NET).<h4>Patients and methods</h4>We performed a retrospective review of patients with clinical stage I-III, HR⁺ breast cancer who received > 90 days of NET at a single comprehensive cancer center between 2004 and 2024.<h4>Results</h4>A total of 230 patients were included; 120 (52.2%) were clinically node-negative (cN0), while 110 (47.8%) were clinically node-positive (cN+). In the cN+ group, 7.3% (8/110) had a nodal pathologic complete response (pCR). In total, 76.4% (84/110) in the cN+ group underwent axillary lymph node dissection (ALND) as the initiaAnnals of surgical oncologyhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC12866965biostudies-literatureAxillary Management after Neoadjuvant Endocrine Therapy (NET).PMC12866965P30 CA016672CA16672Caudle AHwang RFWingate EValero VLitton JHunt KKYi MSingh PLeonard LIbrahim NBedrosian IfalseAxillary Management after Neoadjuvant Endocrine Therapy (NET).<h4>Background</h4>In patients with hormone receptor-positive (HR⁺), HER2-negative breast cancer, there is a lack of data available to define optimal axillary management strategies after neoadjuvant endocrine therapy (NET).<h4>Patients and methods</h4>We performed a retrospective review of patients with clinical stage I-III, HR⁺ breast cancer who received > 90 days of NET at a single comprehensive cancer center between 2004 and 2024.<h4>Results</h4>A total of 230 patients were included; 120 (52.2%) were clinically node-negative (cN0), while 110 (47.8%) were clinically node-positive (cN+). In the cN+ group, 7.3% (8/110) had a nodal pathologic complete response (pCR). In total, 76.4% (84/110) in the cN+ group underwent axillary lymph node dissection (ALND) as the initia2025-01-01T00:00:00Z2025 Dec2026-07-14T21:03:55.804Z2026-06-25T03:08:20.565ZS-EPMC128669654145584710.1245/s10434-025-18916-z